SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Anonymous. UK call for patient adverse drug reaction reporting. Scriptorium 2001; 2634: 4.
  • 2
    van Grootheest K, de Graaf L, de Jong-van den Berg L. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003; 26: 2117.
  • 3
    Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 2007; 63: 14857.
  • 4
    Jarernsiripornkul N, Krska J, Richards RME, Capps PAG. Pharmacist-assisted patient reporting of adverse drug reactions. Pharm J 1998; 261: R33.
  • 5
    Jarernsiripornkul N, Krska J, Capps PAG, Richards RME, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. Br J Clin Pharmacol 2002; 53: 31825.
  • 6
    van Grootheest AC, de Jong-van den Berg L. Review: patients' role in reporting adverse drug reactions. Exp Opin Drug Saf 2004; 3: 3638.
  • 7
    Herxheimer A, Crombag R, Alves TL. Adverse Drug Reactions: A Fifteen-Country Survey & Literature Review. Health Action International Europe, May 2010. Available at http://www.haiweb.org/10052010/10_May_2010_Report_Direct_Patient_Reporting_of_ADRs.pdf (last accessed 11 May 2011).
  • 8
    van Hunsel F, van der Welle C, Passier A, van Puijenbroek E, van Grootheest K. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol 2010; 66: 114350.
  • 9
    van Hunsel FP, ten Berge EA, Borgsteede SD, van Grootheest K. What motivates patients to report an adverse drug reaction? Ann Pharmacother 2010; 44: 9367.
  • 10
    McLernon D, Bind C, Lee A, Watson M, Hannaford P, Fortnum H, Krska J, Anderson C, Murphy E, Avery A on behalf of the Yellow Card Study Collaboration. Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK. Pharmacoepidemiol Drug Saf 2011; 20: 52331.
  • 11
    Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine. Int J Risk Saf Med 2003/2004; 15: 519.
  • 12
    Alshammari TM, Rizwanuddin Ahmad S, Swartz L, Hammad TA. Comparison of adverse drug reaction (ADR) reports submitted to the FDA by consumers and healthcare professionals (HCPs). Pharmacoepidemiol Drug Saf 2009; 18: S1273.
  • 13
    Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010; 362: 8659.
  • 14
    Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell L, Krska J, Lee AJ, Mclernon DJ, Murphy E, Shakir S, Watson M. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess 2011; 15: 1234.
  • 15
    World Health Organisation. Consumer reporting of adverse drug reactions. WHO Drug Inf 2000; 14: 2115.
  • 16
    Hasford J, Goettler M, Munter KH, Müller-Oerlinghausen B. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol 2002; 55: 94550.
  • 17
    Ekman E, Backstrom M. Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden. Eur J Clin Pharmacol 2009; 65: 436.
  • 18
    Biriell C, Edwards IR. Reasons for reporting adverse drug reactions–some thoughts based on an international review. Pharmacoepidemiol Drug Saf 1997; 6: 216.
  • 19
    Backstrom M, Mjorndal T, Dahlqvist R, Nordkvist Olsson T. Attitudes to reporting adverse drug reactions in northern Sweden. Eur J Clin Pharmacol 2000; 56: 72932.
  • 20
    McGuire T, Moses G. What do consumers contribute to pharmacovigilance ? Lessons from the AME line. Conference Proceedings, National Medicines Symposium, National Convention Centre, Canberra 7–9 June 2006. Available at http://www.icms.com.au/nms2006/abstract/132.htm (last accessed 11 May 2011).
  • 21
    Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects. Drug Saf 2007; 30: 66975.